Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center, Non-randomized Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of [18F]Florbetaben Positron Emission Tomography (PET) Imaging to Diagnose Cardiac AL Amyloidosis

NCT05184088 is registered in ClinicalTrials.gov with Lantheus Germany GmbH as lead sponsor.

NCT NCT05184088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05184088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center, Non-randomized Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of [18F]Florbetaben Positron Emission Tomography (PET) Imaging to Diagnose Cardiac AL Amyloidosis
Lead sponsor
Lantheus Germany GmbH
Phase
Phase 3
Overall status
Completed
Start date
January 13, 2023
Completion date
May 5, 2026
Enrollment
244 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

al amyloidosis, attr amyloidosis, cardiac amyloidosis